Drug
OSI-774
OSI-774 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed375%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
NCT00076310
completedphase_2
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT00193154
completedphase_2
Erlotinib in Treating Patients With Advanced Kidney Cancer
NCT00045487
completedphase_2
Tarceva and Capecitabine for Pancreatic Cancer
NCT00125021
Clinical Trials (4)
Showing 4 of 4 trials
NCT00076310Phase 2
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
NCT00193154Phase 2
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT00045487Phase 2
Erlotinib in Treating Patients With Advanced Kidney Cancer
NCT00125021Phase 2
Tarceva and Capecitabine for Pancreatic Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4